Seres Therapeutics amends asset sale agreement with Nestlé to terminate future milestone payments
Seres Therapeutics and Société des Produits Nestlé S.A. amended their August 2024 asset purchase agreement to terminate Nestlé's obligations for second and third sales milestone payments and related interest accruals. The modification reduces Seres' potential future contingent pa
View filing at SEC.gov →